2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - 260-262
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Study Population, Human
PAPER

827 TeclistAMY (EMN40): A phase 2 trial of teclistamab in patients with previously treated light-chain (AL) amyloidosis

Murielle Roussel, MD, PhD, Efstathios Kastritis, MD2, Stefan Schönland, MD, PhD3, K. Martin Kortüm, MD4, Alexander Carpinteiro, MD5, Fiona Kwok, MD6, Giovanni Palladini, MD,PhD7, Monique C Minnema, MD, PhD8, Noemi Horvath, MD9, Margaret Doyle, MSc, BSPharm, PharmD10, Christopher Pericone, PhD11, Jordan Schecter, MD, BS12, Paola Colucci, MSc13, Claudia Priola, MSc14, Chiara Del Pietro15, Sanjay Vara16, Pieter Sonneveld, MD, PhD17, Mario Boccadoro, MD18
1 Hôpital Dupuytren, Limoges, France, Université de Limoges Faculté de Médecine, Limoges, France
2 National And Kapodistrian University Of Athens, Athina, Attiki, Greece
3 University Hospital Heidelberg, Heidelberg, Germany
4 University Hospital Würzburg, Würzburg, Germany
5 Essen University Hospital, Essen, Germany
6 Westmead Hospital, Westmead, New South Wales, Australia
7 Fondazione Irccs Policlinico San Matteo, Pavia, Italy
8 University Medical Center Utrecht, Utrecht, Netherlands
9 Royal Adelaide Hospital, Adelaide Central Business District, South Australia, Australia
10 Johnson&Johnson, Raritan, New Jersey, United States
11 Johnson&Johnson, Raritan, New Jersey, United States
12 Johnson&Johnson, Raritan, New Jersey, United States
13 EMN, Torino, Italy
14 EMN, Torino, Italy
15 EMN, Torino, Italy
16 Johnson&Johnson, Redhill, United Kingdom
17 Erasmus University Medical Center, Rotterdam, Netherlands
18 EMN, Torino, Italy
Background: Systemic AL amyloidosis is a rare disorder caused by the accumulation of monoclonal immunoglobulin free light chain (FLC) derived amyloid fibrils in tissues and organs, leading to serious, or life-threatening organ dysfunction. Treatment relies on multiple myeloma (MM) drugs and targets the FLC-secreting plasma cell clone. Organ responses and survival are related to the rapidity, depth and durability of hematological (Hem) response. Daratumumab (DARA), bortezomib (BOR), cyclophosphamide, and dexamethasone, is the only licensed regimen in AL amyloidosis with high rates of Hem and organ responses; however, some patients (pts) can have suboptimal responses (SOR) or will ultimately relapse. Teclistamab (TEC) is a first-in-class B-cell maturation antigen´CD3 bispecific antibody that has demonstrated deep and durable responses in MM, leading to its approval for triple-class exposed relapse/refractory MM from L2. Data from retrospective case series suggest that TEC may induce rapid and deep Hem and organ responses in pretreated AL pts without unexpected toxicities. The ongoing TeclistAMY (EMN40) trial is evaluating the efficacy and safety of TEC monotherapy in AL pts with SOR to previous therapy or at relapse. Methods: EMN40 is an open-label, single-arm, international, multicenter, phase 2 study (9 centers in 6 countries, NCT06649695). Enrolled pts must have received ³1 line of treatment (Tx) including DARA and BOR, have a measurable disease defined as a difference between involved/uninvolved FLC (dFLC)≥20 mg/L, no cardiac Mayo stage IIIb, an eGFR≥20 ml/min and no symptomatic MM. Following initial step-up doses, TEC was administered at 1.5 mg/kg on days (D) 8,15 of C1; from C2 onwards, TEC was administered monthly at 3 mg/kg. All pts were planned to receive six 28-day cycles and could receive up to 12 cycles if clinically indicated. The primary endpoint was Hem complete response (CR) rate at the completion of C3. Key secondary endpoints included safety, best and overall Hem response rates (ORR), very good partial response (VGPR) rates or better (dFLC≤40 mg/L), time to Hem response and duration, organ responses, major organ deterioration–progression-free survival, time to next therapy, overall survival. We report here the Hem response rates at the completion of C3 (primary endpoint) and preliminary results of toxicities. Results: 30 pts were enrolled and treated between 07/25-06/26. At data cutoff (08/06/26), 14 pts were still on TEC, 14 completed the treatment phase as per protocol, and 2 stopped earlier due to treatment-emergent adverse events (TEAEs) or progression. Median age at inclusion was 68.5 years (range:51-86), 40% of pts were males. Twenty pts had cardiac,18 had renal involvement, and 21 had ≥2 organs involved;18 pts were cardiac Mayo stage II, and 6 stage IIIa; median dFLC was 85.4 mg/L (IQR:62.0-179.5), 6 pts had low dFLC (20-50 mg/L). Seven/12 pts had t(11;14), 5 had 1q gain and 2 had t(4;14). Pts had received a median of 2 (range:1-5) prior lines; all were BOR- and DARA-exposed, 15 IMiDs-exposed, 2 pts had received venetoclax, and 4 an auto transplant. Eleven pts had never achieved ≥VGPR on prior Tx. To date, 29 pts were evaluable for the primary endpoint: 13 (45%) pts achieved CR, with 27 (93%) pts being in ≥VGPR/low-dFLC response at the completion of C3. Hem responses were rapid with 15 pts (52%) reaching ≥VGPR by D8, and 25 (86%) by D15. After C1, the ORR was 96.5% and 90% of pts had a dFLC<10 mg/L. The median time to CR was 1.8 months. No new safety signals were observed in the preplanned analysis after 8 pts completed C1. Overall,10 serious TEAEs were reported in 9 (30%) pts, including 2 pneumoniae, 2 infections NOS, 2 cardiac failure,1 orthostatic hypotension, 1 diarrhea, 1 myositis, and 1 grade (G) 2 cytokine release syndrome (CRS). There was no TEC-related death. Fourteen (46.5%) pts had ≥1 cycle delay of which 9 were due to TEAEs. CRS, , occurred in 16 (53.5%) pts, and 7 (23.5%) received therapeutic tocilizumab. All but one pt reported at least one TEAE, including 13 (45%) with G3/4. The most common TEAEs were infectious (72.5%-10% G3), diarrhea (24%), hematological (24%-17% G3/4), nausea/vomiting (14%), fatigue (14%), cutaneous (10%). Immunoglobulin replacement was given in all pts. Conclusion: TEC monotherapy is a rapidly acting and effective treatment in pretreated AL pts exposed or refractory to DARA and BOR, without unexpected side effects, consistent with established safety profile.
Murielle Roussel, MD, PhD: GSK - Honoraria; J&J - Honoraria; Pfizer - Honoraria; Amgen - Honoraria; Sanofi - Honoraria; J&J - Research Funding; Sanofi - Research Funding; Abbvie - Research Funding